An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer

• Published in: Archives of gynecology and obstetrics Vol. 300; no. 5; pp. 1377 - 1382
• Main Author: Hua, Yu-Ming
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2019; Springer Nature B.V
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer therapies; Disease-Free Survival; Endocrine therapy; Endocrinology; Female; Fulvestrant - pharmacology; Fulvestrant - therapeutic use; Gynecologic Oncology; Gynecology; Human Genetics; Humans; Medicine; Medicine & Public Health; Meta-analysis; Metastasis; Middle Aged; Neoplasm Metastasis; Obstetrics/Perinatology/Midwifery; Treatment Outcome; Endocrine resistance; Targeted agent; Breast cancer; Fulvestrant; Meta-analysis

Background Fulvestrant is approved for the hormone receptor-positive advanced metastatic breast cancer (MBC) patients during or after prior endocrine treatment. The adding of a targeted agent to fulvestrant has improved the outlook for these patients from recent studies. However, these results were...